A part of Watch Media

MedWatchSunday5 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
01/12/2022at 13:15

Analyst proposes four solutions as GN battles with ghosts of debts past

Debt normalization for GN Audio is no longer realistic, says Carnegie analyst Niels Granholm Leth. The debt situation has left GN with four options, two of which are realistic, he assesses.
Photo: Gn / Pr
by christian bundgaard, translated by catherine brett

The elephant in the room for GN Group has long been the firm’s sky-high debt, which the company took on after the acquisition of gaming equipment manufacturer Steelseries.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Gn / Pr

    New GN product will win Veterans Affairs market shares, bank assesses

    For subscribers

  • Photo: Henrik Kastenskov

    Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play

    For subscribers

  • Photo: Pr/gn

    Central Norwegian bank's stake in GN Group drops below 5%

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.
  • Novo Nordisk declared world's best place to work in 2022
  • Novo Nordisk meets upgraded guidance, sets new revenue record

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

For subscribers

Further reading

Per Wold-Olsen has been chairman of Amarin since May 2022 | Foto: Mik Eskestad
Pharma & biotech

Pharmaceutical firm calls special meeting after investor demands Per Wold-Olsen's removal

Amarin Corporation’s chairman, Per Wold-Olsen, who is also chairman of GN Group, has been challenged by a major shareholder in the company, Sarissa Capital.

For subscribers

Photo: Tidsvilde Stine/Ritzau Scanpix
Pharma & biotech

Novo Nordisk declared world's best place to work in 2022

The Best Places to Work organization has released its 2022 list of the best workplaces across the world, and Danish Novo Nordisk shines at the top.

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Miss anything?

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Medical Advisor (Metabolism)

  • Sr. Director, Drug Safety Physician

  • Regulatory Affairs Professional

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Senior Clinical Project Manager

  • Supply Chain Manager

  • Experienced Patent Counsel

  • Commercial Director

  • Application Manager

  • Lead Data Architect

  • Clinical Operational Associate

See all jobs

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Medical Advisor (Metabolism)

  • Sr. Director, Drug Safety Physician

  • Regulatory Affairs Professional

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Senior Clinical Project Manager

  • Supply Chain Manager

  • Experienced Patent Counsel

  • Commercial Director

  • Application Manager

  • Lead Data Architect

  • Clinical Operational Associate

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge